BioSpace News Archive

ONO PHARMA USA, INC. announces its organization and leadership team expansion to advance its clinical development, research alliance, licensing activities, as well as future commercialization opportunities for the upcoming products in the U.S.

Beijing Minhai Biotechnology Co., Ltd. held a signing ceremony with Phil. Pharmawealth, Inc. for their cooperation in jointly promoting the registration, promotion, distribution, marketing, and sales of Beijing Minhai’s 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in the Philippines.

Sensifree LTD, a world innovator in advanced hemodynamic monitoring, received CE certificate for SentiCor-100® in compliance with the new EU MDR.

Isarna Therapeutics will present an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, reported financial results for the three months ended June 30, 2022.

Vivani Medical, Inc., formerly Second Sight Medical, Inc., announced that trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “VANI”.

BIOLASE, Inc., the global leader in dental lasers, announced a strategic plan to partner with postgraduate dental specialty programs throughout North America, to expose new dentists to the benefits of Waterlase technology.

argenx announced that members of management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:00 a.m. E.T. in Boston, MA.

During the quarter, we reached one of the most important milestones in Biovica’s history when the US Food and Drug Administration granted market approval for our assay, DiviTum®TKa, as a tool for monitoring disease progression in post-menopausal women with hormone receptor positive metastatic breast cancer.

Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had received an Innovation Passport from the UK Medicines and Healthcare Products Regulatory Agency for its lead asset - OC134.